Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the…
[ad_1]
Dr. Ciulla presented at The American Academy of Ophthalmology recently…
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the…
NEW YORK, Oct. 7, 2014 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual acuity data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) fo…
[ad_2]
Return to main website.